Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin + R-CVP vs Gemcitabine + R-CVP in First-Line DLBCL Unsuitable for Anthracyclines
NCT01679119Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2013
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in diffuse large B-cell lymphoma (DLBCL), sponsored by University College London. Started Oct 2013; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01679119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01679119.